Attorney Docket No.: 10495.204-US PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: S. Lassen

Confirmation No: 9635

Serial No.: 10/560,224

Group Art Unit: 1652

Filed: December 12, 2005

Examiner: E. Slobodyansky

For: Improved Proteases and Methods for Producing Them

INFORMATION DISCLOSURE STATEMENT (IDS) UNDER 37 CFR 1.97(c)

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which may be material to the patentability of this application and with respect to which there may be a duty to disclose. While the references may be material under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are prior art. The filing of this IDS shall not be construed as a representation that no other material references than those listed exist or that a search has been conducted.

The references are listed in Form PTO/SB/08A, which is in accordance with the requirements of M.P.E.P. 609. A copy of the references is enclosed.

The Examiner's attention is directed to US application no. 10/560,414. The Examiner in that case rejected that case for double patenting in light of the instant case. A copy of the last rejection in that case is included herewith. Applicants urge that the Examiner continuously monitor US application no. 10/560,414 as prosecution continues.

It is respectfully requested that these references be considered by the USPTO in its examination of the above-identified application and be made of record therein.

This IDS is being filed after the period set forth in 37 CFR 1.97(b), but before the mailing date of any of a final action, a notice of allowance, or an action that otherwise closes prosecution.

Accompanying this information disclosure statement is the fee set forth in 37 C.F.R. § 1.17(p). The required fee, estimated to be \$180.00, was charged to Novozymes North America, Inc.'s Deposit Account No. 50-1701 at the time of electronic filing.

Respectfully submitted,

Date: July 21, 2008

/Michael W. Krenicky, Reg. # 45411/ Michael W. Krenicky, Reg. No. 45,411 Novozymes North America, Inc. 500 Fifth Avenue, Suite 1600 New York, NY 10110 (212) 840-0097